A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.

Phase 1 Completed 72 enrolled Boehringer Ingelheim

RandomizedParallel-groupSingle-blindTreatment

Summary

The main objective of this trial is to investigate safety and tolerability of BI 764198 in healthy male subjects following oral administration of single rising doses. Secondary objectives are the exploration of pharmacokinetics (PK) including dose proportionality of BI 764198 after single oral dosing.

Timeline

Start: 2019-03-15
Primary completion: 2019-08-07
Completion: 2019-08-07

Publications

Schultz A, Halabi A, Seitz F, Lemmens K, Wulfrath HS, Lobmeyer MT, Retlich S, Choi W, Soleymanlou N. Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment. Expert Opin Investig Drugs. 2025 May;34(5):415-423. doi: 10.1080/13543784.2025.2510673. Epub 2025 Jun 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BI 764198	Unknown	—	Oral

Indications

No indication recorded.